Loading
A phase 1/2 trial of Puxitatug samrotecan, Rilvegostomig, Saruparib in ovarian cancer and endometrial cancer, run by AstraZeneca, now recruiting.
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies is a phase 1/2 interventional study registered as NCT05123482 by AstraZeneca, with 460 participants planned, started 2021-10-18 and due to reach its primary completion in 2027-09-29. Interventions recorded: AZD8205, AZD8205 and AZD2936 (Rilvegostomig), AZD8205 and AZD5305 (saruparib), AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig), AZD8205 in combination with AZD9574. Conditions listed: Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer. No results are recorded here; the registry entry is the source.
Shares Palacaparib, Saruparib, Endometrial cancer, AstraZeneca.
Shares Puxitatug samrotecan, Endometrial cancer, AstraZeneca, Antibody-drug conjugate (ADC).
Shares Rilvegostomig, AstraZeneca, Antibody-drug conjugate (ADC), Small-cell lung cancer.
Shares Rilvegostomig, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Saruparib, AstraZeneca, Ovarian cancer, Small-cell lung cancer.
Shares Rilvegostomig, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Rilvegostomig, Endometrial cancer, AstraZeneca, Antibody-drug conjugate (ADC).
Shares Rilvegostomig, AstraZeneca, Non-small-cell lung cancer.